You are here

Merck

Merck bags Japanese approval for a weekly diabetes drug

Fierce Biotech

Mon, 09/28/15 - 12:00 pm

Don't be quick to peg Merck's Keytruda in second place for NSCLC, analyst says

Fierce Pharma Marketing

Mon, 09/28/15 - 10:15 am

non-small cell lung cancer

Bristol-Myers Squibb

op-selling drugs might be first in line for Medicare price negotiations

Fierce Pharma

Wed, 09/23/15 - 09:50 pm

Hillary Clinton

Eli Lilly Officially Puts Merck on Notice

Motley Fool

Tue, 09/22/15 - 09:50 am

Boehringer Ingelheim

ANI Pharmaceuticals to Acquire Two NDAs from Merck for $75 Million

Yahoo

Mon, 09/21/15 - 10:27 pm

ANI Pharmaceuticals

corticotropin gel

corticotropin-zinc hydroxide

Merck antibody reduces risk of C. difficile recurrence - study

Yahoo/Reuters

Mon, 09/21/15 - 10:50 am

Merck: Long-acting diabetes pill works same as its Januvia

Yahoo/Reuters

Wed, 09/16/15 - 06:08 pm

The Medicare Gravy Train Into Big Pharma's Pockets Keeps Growing

Seeking Alpha

Mon, 09/14/15 - 10:57 am

Gilead Sciences

Big Pharma's 3 Most Perilous Pipelines

Motley Fool

Sat, 09/12/15 - 01:45 pm

Merck KGaA to try again to get approval for MS pill cladribine

Yahoo/Reuters

Fri, 09/11/15 - 09:57 am

multiple sclerosis

Merck and Samsung notch their first biosimilar victory with Enbrel knockoff

Fierce Biotech

Wed, 09/9/15 - 10:42 am

Samsung Bioepis

rheumatoid arthritis

It's Official, Merck Just Caved. Who's Next?

Motley Fool

Tue, 09/8/15 - 02:05 pm

Bristol-Myers Squibb

Jardiance and its CV data? They're no knockout punch for stalwart Januvia, Merck says

Fierce Pharma

Wed, 09/2/15 - 10:27 am

Boehringer Ingelheim

'No signal' of heart failure risk with Merck's Januvia, analysis confirms

Fierce Pharma

Mon, 08/31/15 - 11:13 am

Did This Clinical Study Just Show Merck's Best-Selling Drug the Door?

Motley Fool

Sun, 08/30/15 - 11:54 am

clinical trials

Boehringer Ingelheim

SGLT2 inhibitor

FDA warns of severe joint pain risk with DPP-4 diabetes drugs

Yahoo/Reuters

Fri, 08/28/15 - 05:52 pm

DPP-4 inhibitor

Boehringer Ingelheim

Intarcia vs. Novo: Which has the most appealing diabetes PhIII program?

Fierce Pharma

Fri, 08/28/15 - 05:44 pm

Can Sprout's Addyi shrug off serious side effects? These blockbusters did

Fierce Pharma Marketing

Wed, 08/26/15 - 09:24 am

Sprout Pharmaceuticals

female sexual dysfunction

GlaxoSmithKline plc, Bayer AG, Merck & Co. Among Pharmaceuticals Most Exposed To Emerging Market Turmoil

Bidness, ETC

Mon, 08/24/15 - 11:34 am

emerging markets

Merck’s Diabetes Dominance at Risk as Rival Drug Helps Out Heart

Bloomberg

Fri, 08/21/15 - 05:24 pm

Boehringer Ingelheim

Pages